Lumira Ventures
Lumira Ventures, established in 2007, is a prominent North American venture capital firm specializing in healthcare and life sciences investments. Based in Toronto, with additional offices in Montreal, Vancouver, and Boston, the firm focuses on emerging, mid, and late-stage companies in biotechnology, biopharmaceuticals, medical devices, digital health, and consumer health sectors. Lumira Ventures invests between $5 million to $15 million, providing not only capital but also active board participation, access to funding sources, partners, and market access to maximize the value of its portfolio companies' technology pipelines. With a 30-year history, the firm has invested in over 100 healthcare companies and currently has a portfolio of 30+ active investee companies across Canada and the United States.
Past deals in Vancouver
Alpha9 Theranostics
Series C in 2024
Alpha9 Theranostics is a biopharma company that focuses on radiotherapeutics for the treatment of solid and hematologic malignancies. The company is creating a strong pipeline of radiopharmaceuticals to target solid and hematologic malignancies. Its systematic approach to radiotherapeutic design is fueled by a toolbox of technologies and chemistries, which offers broad potential for expansion into a multitude of oncology targets. Alpha9 Theranostics was founded in 2019 and is headquartered in Vancouver, Canada.
Zymeworks
Series A in 2016
Zymeworks Inc. is a clinical-stage biopharmaceutical company based in Vancouver, Canada, focused on the discovery, development, and commercialization of innovative biotherapeutics for cancer treatment. The company's lead candidates include ZW25, a bispecific antibody undergoing Phase I and II clinical trials for various tumors, including biliary tract and gastroesophageal adenocarcinomas, and ZW49, a bispecific antibody-drug conjugate in Phase I trials for advanced HER2-expressing cancers. Zymeworks employs a computational biotechnology approach, utilizing proprietary molecular modeling and simulation technologies to optimize therapeutic antibodies and other protein-based therapeutics. The company has established strategic partnerships with notable organizations such as Merck, Eli Lilly, and Bristol-Myers Squibb, as well as collaborations aimed at advancing antibody discovery and development. Founded in 2003, Zymeworks is dedicated to addressing unmet medical needs through its advanced therapeutic platforms and integrated drug development capabilities.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.